Overview

• Mankind Pharma's Q4 FY25 net profit dropped 10.7% year-over-year to ₹4.21 billion, but exceeded analysts’ expectations of ₹3.60 billion.
• Quarterly revenue rose 27% to ₹30.79 billion, fueled by robust growth in chronic therapies and consumer healthcare demand.
• The company completed the integration of its ₹1.6 billion acquisition of Bharat Serums and Vaccines, which bolstered revenue but pressured margins, with EBITDA margin declining to 22.2% from 24.2%.
• Exports surged 88% year-over-year to ₹1,532 crore for FY25, contributing to a 19% rise in total annual revenue to ₹12,207 crore.
• Mankind Pharma retained its position as India’s top pharmaceutical company by prescription count for the eighth consecutive year.